FMO5 and cardiac hypertrophy: Ang-II-induced cardiac hypertrophy is dependent on gp91-containing NADPH oxidase (1) Loss of gp91 mRNA expression (2) Abolition of NADPH oxidase activity, and thus ROS production upon Ang-II infusion (3) Lower basal systolic blood pressure without Ang-II infusion (4) Attenuation of heart/body weight ratio and ANF and beta- MHC mRNA expression (cardiac hypertrophy markers) with Ang-II treatment (5) Decrease in collagen content with Ang-II infusion